Petrovax is organizing the supply of a number of Chinese-made generics to the Russian Federation. The company entered into a licensing agreement with the Chinese Jiangsu Hengrui, a manufacturer of an oncology drug with the active substance camrelizumab, which belongs to PD-1 protein inhibitors – the same class as pembrolizumab (Keytruda from MSD, Pembroria from Biocad) and nivolumab (Opdivo “from BMS). This was reported by the Petrovax press service.
It is expected that the drug will be registered in the Russian Federation in 2024, which will be followed by its localization to the substance stage. Camrelizumab has been approved in China since 2020. The European regulator is also studying its registration dossier.
“Camrelizumab is a molecule with unique indications in oncology, which significantly expands the capabilities of modern medicine. <…> We are increasingly beginning to perceive China as a technological leader,” the message quotes the words of Petrovax President Mikhail Tsyferov. He believes that in 2-4 years, Chinese companies will be able to become absolute leaders in new molecules and will become another source of licensed drugs.
